Hong Kong Stock Movement | FOSUN PHARMA (02196) Surges Over 6% Again as Small Molecule Oral DPP-1 Inhibitor Licensed Overseas, Supporting Revaluation of Innovative Drug Pipeline

Stock News

Aug 15

FOSUN PHARMA (02196) surged over 6% again, rising 5.51% to HK$21.06 at the time of writing, with turnover reaching HK$299 million. On the news front, FOSUN PHARMA recently announced that its controlling subsidiary Fosun Pharma Industry has entered into a License Agreement with Expedition, granting Expedition the rights to develop, manufacture, and commercialize the investigational product XH-S004 globally, excluding mainland China, Hong Kong, and Macau. Expedition will pay up to $120 million in non-refundable upfront and development and regulatory milestone payments, and up to $525 million in sales milestone payments based on annual net sales of the licensed product in the licensed territory. According to a research report, DPP-1 inhibitor drugs have significant market potential. Currently, the company's XH-S004 drug for treating non-cystic fibrosis bronchiectasis is in Phase II clinical trials in China, while its application for treating chronic obstructive pulmonary disease is in Phase Ib clinical trials in China. The company has invested a cumulative 72 million RMB in research and development. This overseas licensing of the company's innovative product, receiving recognition from foreign innovative drug investment and development teams, supports the revaluation of the company's innovative drug pipeline under development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1136084772"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1136084772\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1136084772?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-15 15:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136084772","market":"fut","top_or_hot":-1,"title":"Hong Kong Stock Movement | FOSUN PHARMA (02196) Surges Over 6% Again as Small Molecule Oral DPP-1 Inhibitor Licensed Overseas, Supporting Revaluation of Innovative Drug Pipeline","media":"Stock News","content":"<p>FOSUN PHARMA (02196) surged over 6% again, rising 5.51% to HK$21.06 at the time of writing, with turnover reaching HK$299 million. On the news front, FOSUN PHARMA recently announced that its controlling subsidiary Fosun Pharma Industry has entered into a License Agreement with Expedition, granting Expedition the rights to develop, manufacture, and commercialize the investigational product XH-S004 globally, excluding mainland China, Hong Kong, and Macau. Expedition will pay up to $120 million in non-refundable upfront and development and regulatory milestone payments, and up to $525 million in sales milestone payments based on annual net sales of the licensed product in the licensed territory. According to a research report, DPP-1 inhibitor drugs have significant market potential. Currently, the company's XH-S004 drug for treating non-cystic fibrosis bronchiectasis is in Phase II clinical trials in China, while its application for treating chronic obstructive pulmonary disease is in Phase Ib clinical trials in China. The company has invested a cumulative 72 million RMB in research and development. This overseas licensing of the company's innovative product, receiving recognition from foreign innovative drug investment and development teams, supports the revaluation of the company's innovative drug pipeline under development.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movement | FOSUN PHARMA (02196) Surges Over 6% Again as Small Molecule Oral DPP-1 Inhibitor Licensed Overseas, Supporting Revaluation of Innovative Drug Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movement | FOSUN PHARMA (02196) Surges Over 6% Again as Small Molecule Oral DPP-1 Inhibitor Licensed Overseas, Supporting Revaluation of Innovative Drug Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-15 15:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA (02196) surged over 6% again, rising 5.51% to HK$21.06 at the time of writing, with turnover reaching HK$299 million. On the news front, FOSUN PHARMA recently announced that its controlling subsidiary Fosun Pharma Industry has entered into a License Agreement with Expedition, granting Expedition the rights to develop, manufacture, and commercialize the investigational product XH-S004 globally, excluding mainland China, Hong Kong, and Macau. Expedition will pay up to $120 million in non-refundable upfront and development and regulatory milestone payments, and up to $525 million in sales milestone payments based on annual net sales of the licensed product in the licensed territory. According to a research report, DPP-1 inhibitor drugs have significant market potential. Currently, the company's XH-S004 drug for treating non-cystic fibrosis bronchiectasis is in Phase II clinical trials in China, while its application for treating chronic obstructive pulmonary disease is in Phase Ib clinical trials in China. The company has invested a cumulative 72 million RMB in research and development. This overseas licensing of the company's innovative product, receiving recognition from foreign innovative drug investment and development teams, supports the revaluation of the company's innovative drug pipeline under development.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1136084772","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136084772","pubTimestamp":1755242900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA (02196) surged over 6% again, rising 5.51% to HK$21.06 at the time of writing, with turnover reaching HK$299 million. On the news front, FOSUN PHARMA recently announced that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"港股动静|复星医药(02196)再涨超6%小分子口服DPP-1抑制剂获海外授权支持创新药管线重估","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"600196":1,"02196":1,"06978":1},"content_text":"FOSUN PHARMA (02196) surged over 6% again, rising 5.51% to HK$21.06 at the time of writing, with turnover reaching HK$299 million. On the news front, FOSUN PHARMA recently announced that its controlling subsidiary Fosun Pharma Industry has entered into a License Agreement with Expedition, granting Expedition the rights to develop, manufacture, and commercialize the investigational product XH-S004 globally, excluding mainland China, Hong Kong, and Macau. Expedition will pay up to $120 million in non-refundable upfront and development and regulatory milestone payments, and up to $525 million in sales milestone payments based on annual net sales of the licensed product in the licensed territory. According to a research report, DPP-1 inhibitor drugs have significant market potential. Currently, the company's XH-S004 drug for treating non-cystic fibrosis bronchiectasis is in Phase II clinical trials in China, while its application for treating chronic obstructive pulmonary disease is in Phase Ib clinical trials in China. The company has invested a cumulative 72 million RMB in research and development. This overseas licensing of the company's innovative product, receiving recognition from foreign innovative drug investment and development teams, supports the revaluation of the company's innovative drug pipeline under development.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}